Major Milestone Treatment Completed in P3 Trial for CLBP
Filed with ASX · · 3 pages · English
Story so far
Earlier from Mesoblast
- Becoming a substantial holder
- Ceasing to be a substantial holder
- Quarterly Activities/Appendix 4C Cash Flow Report
- Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
- Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
Later from Mesoblast
- Mesoblast 2026 Full Year Financial Results Webcast
- Notification regarding unquoted securities - MSB
- Appendix 3Y - Philip Krause
- Preliminary Final Report including Appendix 4E
- Annual Financial Results Presentation
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast